| Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care T Papaluca, L McDonald, A Craigie, A Gibson, P Desmond, D Wong, ... Journal of hepatology 70 (5), 839-846, 2019 | 104 | 2019 |
| Terlipressin: current and emerging indications in chronic liver disease T Papaluca, P Gow Journal of gastroenterology and hepatology 33 (3), 591-598, 2018 | 33 | 2018 |
| Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. T Papaluca, SK Roberts, SI Strasser, KA Stuart, G Farrell, G MacQuillan, ... Clinical infectious diseases: an official publication of the Infectious …, 2020 | 25* | 2020 |
| Long-term impact of direct-acting antiviral agent therapy in HCV cirrhosis: critical review SR Fehily, T Papaluca, AJ Thompson Seminars in liver disease 39 (03), 341-353, 2019 | 21 | 2019 |
| HCV elimination: breaking down the barriers to prison based care T Papaluca, A Thompson Hepatoma Research 4, 2018 | 20 | 2018 |
| Scale‐up of hepatitis C treatment in prisons is key to national elimination T Papaluca, ME Hellard, AJV Thompson, AR Lloyd Medical Journal of Australia 210 (9), 391-393. e1, 2019 | 18 | 2019 |
| A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison A Palmer, T Papaluca, M Stoové, R Winter, A Pedrana, M Hellard, ... International Journal of Drug Policy 94, 103203, 2021 | 13 | 2021 |
| The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience RJ Winter, JA Holmes, TJ Papaluca, AJ Thompson Viruses 14 (3), 497, 2022 | 11 | 2022 |
| Retreatment with elbasvir, grazoprevir, sofosbuvir±ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse T Papaluca, M Sinclair, P Gow, S Pianko, W Sievert, N Arachchi, ... Liver International 39 (12), 2285-2290, 2019 | 10 | 2019 |
| Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia T Papaluca, J O’Keefe, S Bowden, JS Doyle, M Stoove, M Hellard, ... Journal of Clinical Virology 120, 84-87, 2019 | 10 | 2019 |
| Reply to:“Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age” Y Shimakawa, M Lemoine Journal of hepatology 73 (5), 1284-1285, 2020 | 9 | 2020 |
| Cyclophosphamide-associated enteritis: A rare association with severe enteritis LS Yang, K Cameron, T Papaluca, C Basnayake, L Jackett, P McKelvie, ... World Journal of Gastroenterology 22 (39), 8844, 2016 | 9 | 2016 |
| Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study T Papaluca, A Craigie, L McDonald, A Edwards, R Winter, A Hoang, ... Open forum infectious diseases 9 (8), ofac350, 2022 | 8 | 2022 |
| Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C T Papaluca, A Craigie, L McDonald, A Edwards, M MacIsaac, JA Holmes, ... PloS one 15 (11), e0242101, 2020 | 7 | 2020 |
| Consensus recommendations on the management of hepatitis C in Australia's prisons RJ Winter, Y Sheehan, T Papaluca, GA Macdonald, J Rowland, A Colman, ... Medical Journal of Australia, 2023 | 6 | 2023 |
| Outcomes of treatment for hepatitis C virus infection in the prison setting L McDonald, A Cragie, J Schulberg, J Scarmozzino, T Papaluca, ... J Hepatol 66 (1), S70-71, 2017 | 6 | 2017 |
| Hepatitis B and pregnancy: understanding the experiences of care among pregnant women and recent mothers in metropolitan Melbourne M Ahad, J Wallace, Y Xiao, C van Gemert, G Bennett, J Darby, ... BMC public health 22 (1), 1-8, 2022 | 5 | 2022 |
| Exploring the feasibility of targeted chronic hepatitis B screening in the emergency department: A pilot study C Brock, Y Yi, T Papaluca, B Lucas, PW Angus, D Taylor, C Leung Emergency Medicine Australasia 30 (6), 864-866, 2018 | 5 | 2018 |
| Effective prison-based treatment and linkage to care after release TJ Papaluca, G Tambakis, D Iser, AJ Thompson The Lancet Infectious Diseases 19 (11), 1171, 2019 | 4 | 2019 |
| In hepatitis C patients with cirrhosis who achieve SVR with treatment, reduction in transient elastography measures does not translate to reduced risk of hepatocellular … J Howell, T Papaluca, S Glasgow, K New, T Hong, J Snell, D Iser, M Ryan, ... Journal of Hepatology 68, S535-S536, 2018 | 4 | 2018 |
